Introduction
The immunosuppressive regimens developed since the discovery of cyclosporine A showed ever increasing efficiency in reducing the severity and occurrence of acute rejection episodes. Recently, a systematic analysis of the literature firmly identified acute rejection events as a bad prognosis factor for long-term graft survival (Wu et al., 2009 ). Since immunosuppressive drugs efficiently control acute rejection, this explains how they significantly improved allograft survival over the past 40 years despite failing to have a direct impact on chronic rejection. The failure of current treatments to control chronic rejection processes combined with their deleterious side-effects urgently call for development of novel therapies against allograft rejection (Kahan, 2003 ; Meier-Kriesche and Kaplan, 2011 ).
During lymphocyte development in primary lymphoid organs, and due to the random rearrangement of genes encoding the antigen receptor, many autospecific T and B cell precursors arise. Since such cells would cause devastating autoimmune pathology, the natural mechanisms involved in the induction of self-tolerance play a crucial role in the survival of the species (Waldmann, 2010 ). Self-tolerance is defined as a state in which autoimmune attack is either prevented or deviated to non-detrimental responses (Walker and Abbas, 2002 ; Hogquist et al., 2005 ). It allows development of protective immunity and is therefore very specific. It appears very attractive to manipulate the mechanisms involved in self-tolerance in order to make them prevent allograft rejection. If successful, this would allow for indefinite survival of grafts.
Tolerance-Induction by Cells of Hematopoietic Origin: Proof of Principle
Several layers of complementary mechanisms ensure tolerance to self-antigens. Interestingly, considerable insight into these mechanisms was obtained through transplantation models and by manipulating the development of the immune system early in life, during embryogenesis or in neonates. Owen ( 1945 ) first observed that dizygotic twin cattle, that almost invariably develop placental anastomosis, “have identical blood types” as adults and he concluded “the critical interchange is of embryonal cells ancestral to the erythrocytes”. Later, Billingham, Medawar, and colleagues showed that these chimeric twins “accepted” each other’s skins when grafted later in life (Billingham et al., 1952 ). In a 1953 landmark paper, the same group showed that skin allograft survival could be substantially prolonged by injecting a single-cell suspension of donor tissues in utero or into neonates (Billingham et al., 1953 ). Such treatment led to varying levels of hematopoietic chimerism, which was later shown to be critically involved in allograft survival (Lubaroff and Silvers, 1973 ; Wood and Streilein, 1982 ; Wren et al., 1993 ; Alard et al., 1995 ).
In the two systems described above, lymphocytes developed in the presence of (and thus learned to be tolerant to) donor antigens. However, in adults the situation is more complicated as, in addition to developing lymphocytes, preexisting donor-specific mature cells would also need to be rendered tolerant. To bypass this concern, several laboratories decided to deplete the pool of mature T cells (Main and Prehn, 1955 ; Trentin, 1956 ; Brocades Zaalberg et al., 1957 ). These groups first experimented this approach through the elimination of all hematopoietic cells. Recipient mice were lethally irradiated or treated with cytotoxic drugs, reconstituted with donor bone marrow, and grafted with skin. These strategies invariably led to substantially increased survival of homo- and xenografts. More recently, Ildstad and Sachs ( 1984 ) definitely validated these observations by inducing long-term survival of allogenic and xenogenic skin grafts using a comparable approach. Similar results were obtained in the rat for heart and skin grafts (Colson et al., 1995b ; Orloff et al., 1995 ). Combined, these observations clearly demonstrated that hematopoietic chimerism leads to prolonged survival of allografts.
Cells of Hematopoietic Origin Induce T Cell Tolerance by Induction of Apoptosis and Anergy
To address the question of how cells of hematopoietic origin induce tolerance, researchers needed a means to identify T cell precursors specific for a given antigen. Kappler et al. ( 1987b ) showed that practically all T cells expressing the variable TCR segment Vβ17a, representing up to 15% of the T cell repertoire in certain mouse-strains, recognized the MHC class II molecule I-E. Given that they had developed an antibody against this Vβ domain, the mechanisms involved in T cell tolerance to I-E could now be analyzed. It was shown in I-E expressing mice that Vβ17a + T cell precursors were eliminated at an immature stage during thymic development (Kappler et al., 1987a ). The following year, the same authors further characterized this mechanism and showed that clonal deletion requires the expression of the negatively selecting ligand by thymic cells of hematopoietic origin (Kappler et al., 1988 ). Many other illustrations of clonal deletion of T cells expressing given TCR Vβ segments by endogenous or exogenous superantigens have since been published (MacDonald et al., 1988b ; Luther and Acha-Orbea, 1997 ).
Could thymic elimination of reactive clones also be involved in the neonatal induction of tolerance to alloantigens? This question was addressed by MacDonald et al. ( 1988a ) who showed that the transfer of superantigen-expressing spleen cells into neonates lead to the intrathymic deletion of superantigen-reactive T cells. Similar conclusions were rapidly drawn by others (Streilein, 1991 ). Later, intrathymic deletion of donor-specific precursors was also reported in adult mixed hematopoietic chimeras using TCR transgenic cells as a tracer population (Manilay et al., 1998 ).
Thus, thymic cells of hematopoietic origin are involved in deletion of autospecific T cell-precursors and mixed hematopoietic chimerism leads to deletion of alloreactive cells. Using thymic organ cultures to analyze the involvement of different stromal cells, it was shown that dendritic cells (DC) are critically involved in this process (Matzinger and Guerder, 1989 ; Jenkinson et al., 1992 ; Anderson et al., 1998 ). This was further confirmed using a transgenic mouse model in which TCR ligand-expression was essentially restricted to DC using the CD11c promoter (Brocker et al., 1997 ). Among the thymic DC subtypes, both Sirpα + and Sirpα − conventional DC have been implicated in central tolerance-induction by deletion (Wu and Shortman, 2005 ; Baba et al., 2009 ). However, other populations of hematopoietic cells may also play a role in this process, including CD4 + CD8 + thymocytes, thymic macrophages and B cells (Pircher et al., 1992 , 1993 ; Kleindienst et al., 2000 ), and circulating peripheral DC (Bonasio et al., 2006 ).
Combined, the data discussed thus far showed that DC, and potentially other cells of hematopoietic origin, contribute to tolerance induction by elimination of developing thymocytes. Using conditioning regimens that totally deplete host T cells before bone-marrow transplantation, it was proposed that this mechanism was necessary and sufficient for maintenance of tolerance and that peripheral mechanisms do not contribute to this process (Khan et al., 1996 ). However, other mechanisms could be involved when less aggressive regimens are used. In normal mice, it has been proposed that deletion of autospecific T cells that escaped thymic selection could also occur in peripheral lymphoid organs and could be involved in the maintenance of self-tolerance (Russell, 1995 ). To test if similar mechanisms were involved in induction of tolerance to alloantigens following bone-marrow transplantation, Wekerle et al. ( 1998 ) tracked T cells specific for a given superantigen in thymectomized mice transplanted with allogeneic bone-marrow under cover of CTLA4-Ig and antibody to CD154 (“co-stimulatory blockade”). They observed a rapid deletion of donor-specific host T cells from the peripheral CD4 + compartment. This observation was later confirmed using a TCR transgenic mouse model (Kurtz et al., 2004 ) and it was further shown that peripheral deletion relies essentially on two types of mechanisms: activation-induced cell death, a Fas-dependent process that can be promoted by IL-2 and that leads to apoptosis of activated T cells when restimulated with high doses of antigen (Lenardo, 1991 ; Ju et al., 1995 ; Russell, 1995 ); and passive cell death or death “by neglect,” a Fas-independent process that can be prevented by overexpression of Bcl-2 or Bcl-x L and that leads to T cell apoptosis when stimulated with low dose of antigen and/or in the absence of co-stimulatory signals (Boise et al., 1995 ; Van Parijs et al., 1996 ; Wekerle et al., 2001 ). It was also shown that in addition to DC, other populations of hematopoietic cells such as B cells have the capacity to delete allospecific precursors from the peripheral T cell compartment (Fehr et al., 2008a , b ). Finally, hematopoietic cells can also cause T cell tolerance by inducing a non-responsive state called clonal anergy (Rammensee et al., 1989 ; Tomita et al., 1994 ; Hawiger et al., 2001 ). Combined, the cited reports clearly show that cells of hematopoietic origin can induce “passive” tolerance (i.e., apoptosis and anergy).
Can Hematopoietic Cells Induce Active Regulatory Mechanisms?
T lymphocytes from chimeric mice in which radioresistant cells express MHC molecules but hematopoietic cells do not, vigorously react to self-antigens in vitro (van Meerwijk and MacDonald, 1999 ) and in some well-defined experimental conditions in vivo (Hudrisier et al., 2003 ). Combined with the observations listed above, this shows that hematopoietic cells play a central role in the deletion and/or functional inactivation of self-reactive precursors. However, passive mechanisms are not sufficient to fully control self-reactivity. Individuals carrying a mutated FOXP3 gene develop the rapidly lethal autoimmune syndrome immuno dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX). This is explained by the fact that Foxp3 is required for the programming of a population of regulatory CD4 + T lymphocytes (Treg) that inhibit and/or divert innate and adaptive immune responses, mainly those directed against self-antigens. Genuine tolerance to self, and consequently probably to non-self-antigens, therefore requires Treg (Fontenot and Rudensky, 2005 ; Sakaguchi et al., 2006 ; Shevach et al., 2006 ).
Given their central (though not exclusive) role in the control of autoimmune responses, it was probably not a very surprising finding that the Treg repertoire is strongly enriched in autospecific cells (Romagnoli et al., 2002 ; Hsieh et al., 2004 ). Development of self-antigen-specific Treg in the thymus depends on interaction of developing precursors with MHC/self-peptide ligands expressed by thymic epithelial cells (Bensinger et al., 2001 ; Romagnoli et al., 2005 ; Ribot et al., 2006 , 2007 ; Aschenbrenner et al., 2007 ). Moreover, the transplantation of allogeneic thymic anlagen (i.e., the initial cluster of pluripotent embryonic cells from which the thymus will develop) into mice induces Treg-mediated tolerance to subsequent skin grafts of the same donor, again showing that thymic epithelial cells can select antigen-specific Treg (Le Douarin et al., 1996 ). However, the capacity to trigger Treg differentiation in the thymus is not a property restricted to epithelial cells as it has been reported that thymic DC are also involved in this process (Watanabe et al., 2005 ; Proietto et al., 2008 ; Wirnsberger et al., 2009 ). Moreover, induction of Treg differentiation by DC has also been reported in peripheral lymphoid organs under certain carefully controlled experimental conditions (reviewed by Romagnoli et al., 2008 ). It may therefore be hypothesized that hematopoietic chimerism can lead to differentiation and/or expansion of Treg specific for donor antigens and thus to the development of dominant tolerance. However, in experimental systems where the conditioning regimen used to induce mixed hematopoietic chimerism involved the total deletion of host T cells, transfer of syngeneic naïve CD4 + T cells into the recipient leads to bone-marrow rejection and to the concomitant loss of donor-specific transplantation tolerance (Wren et al., 1993 ). This result clearly demonstrated that hematopoietic chimerism per se is insufficient for induction of dominant tolerance to alloantigens. Given the non-redundant role of Treg in maintenance of self-tolerance, hematopoietic chimerism therefore appears unlikely to be sufficient for permanent survival of allografts.
Active tolerance mechanisms are not limited to those mediated by Treg. “Immune deviation” from a harmful Th1 to a less detrimental Th2 response has also been shown to play a role in control of immune responses (Rocken, 1996 ; Walker and Abbas, 2002 ). Alloreactive Th2 cytokine producing T cells have been observed after neonatal injection of lymphohematopoietic cells (Streilein, 1991 ) and immune deviation by IL-4 was shown to play a critical role in tolerance to alloantigens (Donckier et al., 1995 ). The hematopoietic (micro-)chimerism induced in this experimental model, which is critically required for the allograft tolerance (Lubaroff and Silvers, 1973 ), therefore appears to induce an active regulatory mechanism. However, this mechanism appears insufficient for induction of full immunological tolerance to alloantigens (see below). Stem-cell transplantation under cover of cyclophosphamide can induce tolerance to MHC-matched skin allografts in mice. It was shown that NKT cells, another immunoregulatory population, play a central role in this phenomenon (Iwai et al., 2006 ). Regulatory T cell populations other than Foxp3 + cells may therefore be induced by hematopoietic chimerism but their activity appears insufficient for prevention of chronic allograft rejection.
Does Hematopoietic Chimerism Induce Genuine Tolerance to Allografts?
As discussed above, hematopoietic chimerism is thought to be sufficient for induction of tolerance to allografts. The mechanisms involved include central and peripheral clonal deletion and anergy. After the initial reports on allograft tolerance in dizygotic cattle twins that had shared blood circulation during embryonic life, it became clear that most skin grafts were rejected in the long term (Stone et al., 1965 , 1971 ). Second skin grafts from the same donor survived less long than the first grafts, but substantially longer than third party organs, showing that the tolerance mechanism had not waned away.
Also neonatal injection of allogeneic splenocytes, leading to hematopoietic microchimerism, is thought to induce tolerance to subsequent skin grafts. However, this procedure appeared to work only in a limited number of donor/host combinations. Importantly, most of the reported donor/host combinations concerned MHC congenic strains (i.e., expressing distinct MHC haplotypes on an identical genetic background) and chronic rejection was not systematically studied (Streilein and Klein, 1977 ). Moreover, even when acceptance of skin allografts was achieved, it did not correlate with immunological unresponsiveness (Streilein, 1991 ; Donckier et al., 1995 ).
In adult mice, lymphoablation was achieved using lethal total body irradiation or depleting antibodies to, e.g., CD4 and CD8. Myeloablation, required for induction of hematopoietic chimerism, was induced by the irradiation or administration of myeloablative drugs. Subsequent transplantation of allogenic or xenogenic bone marrow led to persistent chimerism (reviewed in Wekerle and Sykes, 1999 ; Cosimi and Sachs, 2004 ). Skin grafts from the bone-marrow donors could survive for prolonged periods, but success-rates were often well below 100% and chronic rejection was not studied. In some host/donor combinations, hematopoietic chimerism failed to prevent acute rejection of skin allografts (Boyse et al., 1970 ), and T cell reactivity to skin-specific antigens not expressed by hematopoietic cells was responsible for this observation (Scheid et al., 1972 ; Boyse et al., 1973 ). Also the survival of cardiac allografts was favored by hematopoietic chimerism (Steinmuller and Lofgreen, 1974 ). However, histological analysis of surviving hearts revealed frequent chronic rejection (Russell et al., 2001 ). Also in the rat, myelo- and lymphoablation followed by induction of hematopoietic chimerism was reported to prolong survival of skin, heart, and renal allografts (Slavin et al., 1978 ; Colson et al., 1995b ; Orloff et al., 1995 ; Blom et al., 1996 ). However, chronic rejection was seldom adequately studied. It appears therefore that immunological tolerance to allografts is not systematically achieved by induction of hematopoietic chimerism in lymphoablated recipients.
Hematopoietic chimerism can also be induced with non-lymphoablative regimens. Surprisingly, under certain of these conditions, allografts appear to do better than when lymphoablative conditioning is used (Table 1 ). Blocking the T cell co-stimulatory molecule CD28 with an Ig-fusion protein of its CTLA4-ligand (CTLA4-Ig), combined with inhibition of the CD40/CD40L (i.e., CD154) pathway involved in activation of antigen presenting and B cells, substantially prolongs heart and skin allograft survival (Larsen et al., 1996 ). However, histological signs of chronic rejection of cardiac allografts was observed in all thus conditioned mice (Shirasugi et al., 2002 ). When co-stimulatory blockade was combined with induction of hematopoietic chimerism, heart, skin, and also intestine allografts survived substantially longer and no chronic rejection was observed (Wekerle et al., 1998 , 2000 ; Adams et al., 2001 ; Shirasugi et al., 2002 ; Guo et al., 2003 ). Transplantation tolerance in such settings was dominant and depended on Treg, at least during early stages (Bigenzahn et al., 2005 ; Domenig et al., 2005 ).
Table 1
Combined bone-marrow and organ transplantation in the mouse: non-myelo- and lymphoablative procedures .
a α, antibody to; BUS, busulfan; CP, cyclophosphamide; nd, non-depleting; SC, CD34+ stem cells; TBI, total body irradiation; TI, thymic irradiation; Treg, CD4+CD25+ regulatory T cells . b N/D, not detected .
| BM/SC graft => host | Organ/tissue graft | Conditioning a | Hematopoietic chimerism b | Allograft survival | Reference |
| ANTIBODIES | |||||
| No BM, C3H host | BALB/c heart | αCD154 and CTLA4-Ig | 7/7 > day 70 (no chronic rejection at d63) | Larsen et al. ( 1996 ) | |
| BALB/c skin | 15/15 > day 50 (no chronic rejection at day 50) | ||||
| B10.A => B6 | B10.A skin | αCD154 and CTLA4-Ig | Persistent | 8/8 at day 145 | Wekerle et al. ( 2000 ) |
| Transient | 1/5 at day 145 | ||||
| B10.A => B6 | B10.A skin | αCD154 and CTLA4-Ig, sublethal TBI | Persistent | 7/9 at day 160 | Wekerle et al. ( 1998 ) |
| BALB/c => B6 | BALB/c skin | αCD154 and CTLA4-Ig, BUS | Persistent | 7/7 at day 250 | Adams et al. ( 2001 ) |
| BALB/c => B6 | BALB/c heart | αCD154 and CTLA4-Ig | Undetectable | 8/9 at day 180, chronic rejection at day 300 in 8/8 hosts | Shirasugi et al. ( 2002 ) |
| αCD154 and CTLA4-Ig, BUS | Persistent | 5/5 at day 180, no chronic rejection at day 300 | |||
| BALB/c => B6 | BALB/c intestine | αCD154 and CTLA4-Ig, BUS | Persistent | 5/7 at day 92 | Guo et al. ( 2003 ) |
| BALB/c => B6 | BALB/c skin | αCD154 and CTLA4-Ig, Rapa, Treg | Persistent? | 7/7 at day 170 | Pilat et al. ( 2010 ) |
| BALB/c => B6 | BALB/c skin | low dose TBI, αCD154 | Persistent | 0/4 at day 60 | Luo et al. ( 2007 ) |
| B6.C-H-2 d skin | 4/4 > day 180 | ||||
| BALB/c => B6 | BALB/c skin | αCD154 andαLFA-1 | Persistent | 4/7 > day 270 | Metzler et al. ( 2004 ) |
| αCD154 and Rapa | 4/7 > day 226 | ||||
| αCD154 and BUS and various | 22/24: chronic rejection | ||||
| BALB/c heart | 4/24: mild chronic rejection | ||||
| BALB/c skin | αLFA-1 and Rapa | 0/6 day 117 | |||
| BALB/c => B6 | BALB/c pancreatic islets | Rapa, low dose TBI | Persistent | 6/6 > day 100 | Luo et al. ( 2005 ) |
| B10.BR => CBA | B10.BR skin | αCD4 andαCD8(nd) | Persistent | 8/8 at day 240 | Qin et al. ( 1990 ) |
| B10 DST => C3H | C3H heart | αCD4(nd) | N/D | 7/7 at day 100 | Pearson et al. ( 1992 ) |
| DRUGS | |||||
| BALB/c => B6 | BALB/c skin | SC, CP, αThy1 | Persistent | 10/15 at day 159 | Mayumi and Good ( 1989 ) |
| BALB/c = > C3H | BALB/c skin | 7/8 at day 165 | |||
| B6 => C3H | B6 skin | 4/9 at day 185 | |||
| C3H => B6 | C3H skin | 0/19 (chronic rejection) | |||
| B10.BR or BALB/c => B10 | B10.BR or BALB/c skin | Sublethal TBI, CP | Persistent | 9/10 at day 60 | Colson et al. ( 1995a ) |
| BALB/c => B10 | BALB/c heart | 6/6 > day 420 | |||
| B10.A(5R) => B10 | B10.A(5R) skin | SC, CP | Transient | 4/10 at day 200 | Tomita et al. ( 1990b ) |
| C3H => AKR | C3H skin | SC, CP | Transient | 5/8 at day 100=> | Tomita et al. ( 1990a ) |
| B10.BR => AKR | B10.BR skin | 5/6 at day 100 | |||
| AKR => C3H | AKR skin | 5/8 at day 100 | |||
| B10.BR => C3H | B10.BR skin | 4/8 at day 100 | |||
| B10.D2 => BALB/c | B10.D2 skin | 5/6 at day 100 | |||
| B10 => AKR | B10 skin | 0/6 at day 12 | |||
| B6 => C3H | B6 skin | 0/6 at day 13=> | |||
| B6 => AKR | B6 skin | 0/6 at day 12 | |||
| AKR SC => C3H | AKR skin | CP | Persistent | 9/10, day 120 | Eto et al. ( 1990 ) |
| AKR SC => C3H | B10.BR skin | 0/5 at day 13 | |||
| B10.BR SC => C3H | B10.BR skin | 10/10 at day 120 | |||
| B10.BR SC => C3H | AKR skin | 0/5 at day 14 | |||
| DBA/2 => BALB/c | DBA/2 skin | 8/10 at day 80 | |||
| DBA/2 => BALB | B10.D2 skin | 0/5 at day 13 | |||
| DBA/2 SC => BALB/c wt | DBA/2 skin | CP | Persistent | 6/6 at day 100 | Iwai et al. ( 2006 ) |
| DBA/2 SC => Vα14 NKT KO | 0/6 at day 50 | ||||
| B10.A => B6 | B10.A skin | αCD4(d) and αCD8(d), CP, TI, TBI | Persistent | 6/6 at day 100 | Mapara et al. ( 2001 ) |
Combined, these data indicate that hematopoietic chimerism per se appears insufficient for induction of transplantation tolerance. However, when combined with conditioning regimens that allow for development of dominant tolerance, prevention of chronic rejection can be achieved.
Induction of Hematopoietic Chimerism: Toward the Clinic
Given the very encouraging results obtained with mixed hematopoietic chimerism in rodents, several groups have attempted to induce hematopoietic chimerism and transplantation tolerance in large animal models (Wekerle and Sykes, 1999 ; Cosimi and Sachs, 2004 ; Horner et al., 2006 ). Experimental protocols are necessarily more complex than in rodents since adult recipients were used and high dose whole body irradiation is associated with a too high level of morbidity. A combination of immunosuppressive drugs and antibodies, as well as lower levels of irradiation or irradiation limited to lymphoid organs, was therefore used as conditioning regimen (Table 2 ). In miniature swine, a preconditioning of T cell depletion, low dose total body irradiation, thymic irradiation, and splenectomy, followed by bone-marrow and skin transplantation, led to persistent hematopoietic chimerism in five out of six animals. Four of these animals were transplanted with donor skin. Half of these animals appeared to accept, but the other half rejected the skin allografts (Fuchimoto et al., 2000 ). Also using a milder conditioning regimen, persistent chimerism was obtained in miniature swine and one out of two skin grafts appeared to be permanently accepted (Fuchimoto et al., 2000 ). When the latter protocol was used for kidney transplantation, four out of four allografts survived more than 100 days (Fuchimoto et al., 2000 , 2001 ). Therefore, as observed in rodents, persistent hematopoietic chimerism led to an incomplete level of allograft tolerance that appeared efficient for protection of poorly immunogenic organs such as kidney but fails to prevent rejection of highly immunogenic skin allografts.
Table 2
Combined bone-marrow and organ transplantation in large animals and non-human primates .
a α, antibody to; αCD3-DT, anti-CD3 antibody coupled to diphtheria toxin; ALS, anti-lymphocyte serum; ATG, antithymocyte globulin; BM, bone marrow; CP, cyclophosphamide; PBSC, peripheral blood stem cells; TBI, total body irradiation; TI, thymic irradiation; TLI, total lymphoid irradiation . b Renal allografts that were not rejected but were lost for other reasons . c N/A, not analyzed; N/D, not detected . d Animals that rejected their allografts are indicated in bold . e Renal allografts that were not rejected but were lost for other reasons .
| Species | Organ | Conditioning a | Immunosuppression | Hematopoietic chimerism c | Allograft survival d | Reference |
| “Cattle” | Skin | Co-twins | None | Persistent | 30% at 2 years | Stone et al. ( 1971 ) |
| Body skin | Co-twins | None | Persistent | 0/10 at day 68 | Emery and McCullagh ( 1980 ) | |
| Auricular skin | 5/12 > day 60 | |||||
| Dog | Heart | TLI, donor BM | ±ATG, ±MTX, ±CsA | N/A | 0/29 at day 329 | Strober et al. ( 1984 ) |
| Kidney | ALS, donor BM | None | N/A | >14 b , >17 b , >38 b , >78 b d, ≤ 4/24 | Caridis et al. ( 1973 ) | |
| Kidney | ALS, donor BM | None | N/A | 0/13 at day 300 | Hartner et al. ( 1986 ) | |
| Miniature swine | Kidney | Lethal TBI ± CP | None | Persistent | >200, >200, >200, >200, 75 | Guzzetta et al. ( 1991 ) |
| Skin | αCD3-DT; TBI; TI; donor BM | 30 days CsA | Persistent | 45, 50, >50, >235 days | Huang et al. ( 2000 ) | |
| Skin | αCD3-DT; TI; donor PBSC | 30 days CsA | Persistent | >300, 45 days | Fuchimoto et al. ( 2000 ) | |
| Kidney | >120, >180, >100 days, “long term” | Fuchimoto et al. ( 2000 , 2001 ) | ||||
| Rhesus monkey | Kidney | ATG, donor BM | None | N/A | 20% at day 240 | Thomas et al. ( 1983 , 1987 ) |
| Cynomolgus monkey | Kidney | ATG; TBI; TI; splenectomy; donor BM | 4 weeks CsA | Transient | >3478, >2569, >834 e , >771 e , >405 e , 260, >198 e , >196 e , >137 e , 72, 44, 40, 37, 40, 37 days | Kawai et al. ( 1995 ), Kimikawa et al. ( 1997b ), Kawai et al. ( 2002 , 2004 ) |
| N/D | 14, 175 days | |||||
| Heart | Transient | 509, 428, 138 days | ||||
| N/D | 56, 43 days | |||||
| Kidney | ATG; TBI; TI; donor BM | 4 weeks CsA | Transient | 117, 95, 43 | ||
| Kidney | ATG; TBI; TI; donor BM; aCD154 | 4 weeks CsA | Transient | >1710, >1167, 755, 206, 837, 401, 373, 58 | Kawai et al. ( 2004 ) |
In Cynomolgus monkeys, a preconditioning regimen was used that consisted of T cell depletion, low dose total body irradiation, thymic irradiation, and splenectomy, followed by bone-marrow and kidney transplantation (Kawai et al., 1995 , 2002 , 2004 ; Kimikawa et al., 1997b ). Only transient hematopoietic chimerism was observed, but nevertheless 8 out of 15 grafts did not show signs of rejection (Table 2 ). An acute cellular rejection process led to the loss of the other grafts (Kimikawa et al., 1997a ; Kawai et al., 1999 ). A similar preconditioning regimen was used for monkeys that received a cardiac allograft. Three out of five animals developed transient chimerism, but all five hearts were eventually lost by a rejection-process characterized by cellular infiltrates (Kawai et al., 2002 ). The observation that kidney allografts were more likely to be accepted than heart allografts confirmed earlier data on transplantation in miniature swine that, interestingly, also showed that kidneys can play an important role in tolerance to heart allografts (Madsen et al., 1998 ; Mezrich et al., 2003a , b ). Taken together these data highlight the difficulty to obtain an efficient and persistent engraftment of hematopoietic stem cells in large animal models. When only transient, hematopoietic chimerism induces tolerance mechanisms that are probably different from and less efficient than those induced in hosts with long-term persistence of hematopoietic donor cells.
Induction of Hematopoietic Chimerism: In the Clinic
Based on the promising results in monkeys, induction of hematopoietic chimerism for prevention of allograft rejection has also been performed in humans (Table 3 ). Infusion of donor bone-marrow showed some beneficial effect in renal allograft recipients (Monaco, 2003 ). Interestingly, in an early report in which large numbers of patients were described, infusion of donor bone marrow, leading to transient chimerism, inhibited acute but not chronic rejection (Barber et al., 1991 ; McDaniel et al., 1994 ). One of the first reported cases of long-term allograft survival achieved by induction of hematopoietic chimerism concerned a woman with end-stage renal disease secondary to multiple myeloma (Spitzer et al., 1999 ). The patient received an immunosuppressive but non-myeloablative conditioning regimen. HLA-matched bone marrow and kidney from the patient’s sister were transplanted and the immunosuppressive drug cyclosporine A administered for 73 days. Whereas the hematopoietic chimerism disappeared after discontinuation of immunosuppression, the kidney remained functional for at least another 7 years (Fudaba et al., 2006 ). In total, six multiple myeloma patients receiving this treatment have been reported and all maintained renal function after discontinuation of immunosuppression for 2–7 years (Spitzer et al., 1999 ; Buhler et al., 2002 ; Fudaba et al., 2006 ). Stem-cell transfusion was also shown to have a beneficial effect in liver transplantation (Donckier et al., 2004 ). Another example concerned a patient with end-stage renal disease who received an HLA-matched kidney graft. The conditioning regimen, which included total lymphoid irradiation, immunosuppression, and a graft of mobilized CD34 + stem cells, led to persistent hematopoietic chimerism. At the time of publication, the renal graft had remained functional for 34 months (Scandling et al., 2008 ).
Table 3
Combined bone-marrow and organ transplantation in humans .
a α, antibody to; ALG, anti-lymphocyte globulin; ARA-C, arabinofuranosyl cytidine; ATG, antithymocyte globulin; BM, bone marrow; CsA, cyclosporin A; CP, cyclophosphamide; HSC, CD34+ hematopoietic stem cells; PBSC, peripheral blood stem cells; Pred, prednisone; Rapa, Rapamycin; TBI, total body irradiation; TI, thymic irradiation; TLI, total lymphoid irradiation . b Patients that rejected their allografts are indicated in bold . c N/A, not analyzed; N/D, not detected .
| Organ | Conditioning a | Immunosuppression a | Hematopoietic chimerism c | Allograft survival b | Reference |
| Kidney (HLA-matched) | ALG; CP ALG; CP; donor BM | Maintenance CsA; azathioprine; prednisone | N/A | 13 /54 rejected 3 /57 rejected | Barber et al. ( 1991 ) |
| Kidney | Donor BM | 2 weeks ALG + maintenance | Persistent microchimerism Transient/ND | 21/23 at 1 year (but “chronic rejection”) 1/7 at 1 year | McDaniel et al. ( 1994 ) |
| Kidney (haplocompatible) | TBI, ARA-C, CP, ATG (splenectomy) | 10 months CsA, Pred | Persistent | >15 months | Sorof et al. ( 1995 ) |
| Kidney (related donors) | Not specified, prior BM transplantation to treat hematological disorders | None | Persistent | >15, >30, >3 months | Butcher et al. ( 1999 ) |
| Kidney (HLA-matched) | CP; ATG; TI; donor BM | 2 months CsA | Transient/persistent | >7.3, >5.3, >4.3, >3.5, >2.8, >2 years | Spitzer et al. ( 1999 ), Buhler et al. ( 2002 ), Fudaba et al. ( 2006 ) |
| Kidney (HLA-matched) | ATG; TLI; donor PBSC | 6 months CsA | Persistent | >34 months | Scandling et al. ( 2008 ) |
| Kidney (HLA-mismatched) | CP; αCD2; TI; donor BM | ≤14 months CsA/Rapa | Transient | >1932, >1666, 10 days , >1050, >707 days; donor-specific antibodies | Kawai et al. ( 2008 ), Porcheray et al. ( 2009 ) |
| Pancreatic islet (HLA-mismatched) | High dose HSC | 1 year “Edmonton” (FK506, Rapa) | Transient | 451, 480, 178, 471, 158, 510 days | Mineo et al. ( 2008 ) |
| Liver | ATG; CP; donor HSC | 28–90 days FK506, Rapa | Transient/ND | >240, >290 | Donckier et al. ( 2004 ) |
Induction of hematopoietic chimerism followed by kidney transplantation was also performed with HLA single haplotype mismatched grafts (Kawai et al., 2008 ), a clinically important setting. Five patients with end-stage renal disease received an immunosuppressive but non-myeloablative preparative regimen and a combined bone-marrow/renal allograft. All developed a transient multi-lineage chimerism. Whereas one patient lost the allograft by acute humoral rejection 10 days post transplantation, four out of the five patients, treated with a combination of immunosuppressive drugs for up to 14 months, maintained renal function for up to 1400 days thereafter. Renal biopsies showed normal tissue for three of these patients, with some minor signs of chronic rejection for the fourth. In vitro studies suggested specific absence of T cell-responses to directly presented alloantigens. However, two out of the four patients later developed alloantibodies, one showing complement depositions in the graft (Porcheray et al., 2009 ). It needs to be emphasized that T cell reactivity to indirectly presented donor antigens is required for alloantibody-production by host B-lymphocytes. The apparent absence of T cell response to directly presented alloantigens and the production of alloantibodies are therefore not in contradiction. Combined, these studies suggested that long-term acceptance of (though not genuine immunological tolerance to) kidney allografts can be obtained by a therapy including induction of transient hematopoietic chimerism and therefore represented a major step forward in transplantation medicine.
Less promising results were obtained in a study in which HLA-mismatched pancreatic islets were transplanted into type I diabetes patients (Mineo et al., 2008 ). The conditioning regimen used was very mild but nevertheless led to transient hematopoietic chimerism. However, all four patients that initially adhered to immunosuppressive therapy lost graft-function rapidly after drug weaning.
A Role for Regulatory T Cells in Hematopoietic Chimerism-Associated Tolerance?
At this point, one might wonder if more work is warranted to obtain tolerance to (and therefore permanent acceptance of) organ allografts. When considering the very promising results obtained with kidney allografts in humans, one has to keep in mind that this organ might represent a special case. The human islet study failed, and the monkey and swine studies gave substantially less satisfying results with skin and heart allografts than with renal transplants. Moreover, in miniature swine it was shown that kidney allografts induced tolerance to heart allografts (Madsen et al., 1998 ). The thymus and Treg may play a role in this phenomenon (Yamada et al., 1999 ; Mezrich et al., 2003a ).
To induce genuine immunological tolerance to donor tissues, hematopoietic chimerism needs to persist in the long term to continuously induce tolerance of newly developing lymphocytes in primary lymphoid organs. Indeed, if hematopoietic chimerism is only transient, mature allospecific lymphocytes will develop and, in the absence of dominant tolerance mechanisms, will eventually destroy the graft. Long-term hematopoietic chimerism has been achieved with very aggressive conditioning regimens inducing total host T cell depletion. However, the level of toxicity and the severe immunosuppression associated with this type of treatment do not allow their use in the clinic. Alternative conditioning regimens have been envisaged to avoid rejection of donor bone marrow while allowing for survival of part of the host T cells. They included the injection of non-depleting antibodies to block T cell co-stimulatory pathways and the injection of antibodies specific for some T cell markers upregulated upon activation. As described throughout this review, these methods gave very promising results in rodents. However, induction of a permanent chimerism was far more difficult to achieve in large animals. This observation might be largely responsible for the less satisfying results obtained with heart and skin allograft in miniature swine and primates. Moreover, antibody-based therapies can also generate unpredicted side effects that complicate translation into the clinic. For example, the use of anti-CD154 antibody in a non-human primate renal allograft model led to severe thromboembolic complications (Kawai et al., 2000 ; Koyama et al., 2004 ) due to CD154 expression on activated platelets and to CD40 expression on the vascular endothelium (Henn et al., 1998 ; Slupsky et al., 1998 ). The use of anti-CD154 has also been associated with impaired humoral immunity against influenza in a heart allograft model (Crowe et al., 2003 ). Antibodies targeting other T cell surface markers also present limitations as targeted molecules can be expressed by other populations, e.g., CD25 on Treg. While inhibiting the allogeneic response, such approaches could therefore prevent the establishment of regulatory mechanisms important for graft survival. They also non-specifically inhibit T cell-dependent immunity, including protective responses against pathogens. Finally, most of the protocols used in large animals or currently tested in the clinic require strong initial immunosuppressive treatments that induce major qualitative and quantitative modifications of the immune system that last for years. In conclusion, while highly promising, these strategies still need to be optimized before going into the clinic.
To overcome the issues listed above, several laboratories embarked on studies to evaluate the potential of Treg to promote allograft protection (reviewed by Li and Turka, 2010 ). The capacity of naturally occurring Treg to control allogeneic responses was already highlighted by Sakaguchi et al. ( 1995 ) landmark paper. Using in vivo activated polyclonal Treg with irrelevant specificity, Karim et al. ( 2005 ) first induced tolerance to allogeneic skin graft in lymphopenic Rag-deficient hosts reconstituted with naïve CD45RB high CD4 + T cells (Karim et al., 2005 ). Similar results were obtained in another lymphopenic system with in vitro expanded donor-specific Treg (Golshayan et al., 2007 ). Interestingly, this approach also significantly prolonged skin allograft survival in unmanipulated wild-type hosts. In a transplantation-model across minor histocompatibility antigens, another group protected male skin graft from rejection by syngeneic female hosts using Foxp3-transduced male antigen-specific TCR transgenic CD4 + T cells (Chai et al., 2005 ). In another study, a genetically manipulated Treg population with direct and indirect alloantigen-specificity substantially prolonged skin allograft survival and delayed chronic rejection of heart allografts when co-injected with anti-CD8 antibody (Tsang et al., 2008 ). More recently, prevention of transplant arteriosclerosis and long-term survival of skin allograft were achieved with in vitro expanded naturally occurring CD127 low CD25 + CD4 + human Treg in a chimeric humanized mouse system (Issa and Wood, 2010 ; Nadig et al., 2010 ). Combined, these reports demonstrated the capacity of Treg to delay rejection processes.
Based on the large body of literature on transplantation tolerance through hematopoietic chimerism and on the immunosuppressive potential of Treg, several laboratories decided to combine Treg infusion with bone-marrow transplantation (Figure 1 ). This method is expected to allow the establishment of complementary tolerance mechanisms, thus mimicking the complex network of checkpoints and regulatory systems naturally involved in maintenance of self-tolerance (Figure 2 ). Moreover, in addition to their general modulatory effects on the reactivity of the immune system, Treg expressing the transcription factor Foxp3 have the capacity to establish an immune-privileged niche for allogeneic hematopoietic stem cells after transplantation into non-irradiated recipients (Fujisaki et al., 2011 ). The co-injection of Treg with allogeneic bone-marrow should therefore promote its engraftment. Administration of donor-specific Treg prevented rejection of bone-marrow allografts in preconditioned mice (Joffre et al., 2004 ; Joffre and van Meerwijk, 2006 ). Promising results were later obtained using polyclonal donor Treg (Hanash and Levy, 2005 ). However, similar protocols failed to substantially prolong survival of skin and heart allografts (Joffre et al., 2008 ; Tsang et al., 2008 ; Pilat et al., 2010 ). In contrast, when combined with bone-marrow transplantation, administration of a single dose of Treg fully prevented rejection of skin and heart (Joffre et al., 2008 ). Whereas Treg specific for directly presented donor-antigens allowed for survival of bone-marrow allografts, they failed to prevent chronic rejection of skin and heart. In contrast, Treg specific for indirectly presented donor-antigens fully prevented chronic heart and skin allograft rejection (Joffre et al., 2008 ). These results firmly demonstrated the clinical potential of Treg infusion in induction of bone-marrow chimerism and in the subsequent prevention of acute and chronic allograft rejection.


Treg and Hematopoietic Chimerism-Based Strategies: Some Limitations to Overcome
The data described above constitute a proof of principle that combining Treg and bone-marrow infusion can lead to subsequent tolerance to allogeneic tissues, even in very stringent donor/host combinations and for highly immunogenic tissues such as the skin. However, 5 Gy total body irradiation was required in that protocol (Joffre et al., 2008 ). This dose appears not suitable for clinical use as it is associated with severe temporary leukopenia. Interestingly, the group of Wekerle recently induced hematopoietic chimerism in mice using a comparable approach, but without or with very limited cytoreductive conditioning (Pilat et al., 2010 , 2011 ). Treatment with costimulation-blocking agents, a short course of rapamycin, and injection of polyclonal Treg allowed for induction of hematopoietic chimerism. Skin grafts transplanted on these mice survived for more than 160 days, without signs of rejection or appearance of donor-specific antibodies (Pilat et al., 2010 ). More recently, this group raised similar conclusions using polyclonal host CD4 + lymphocytes previously transduced with a retroviral vector containing Foxp3 and a drug-free conditioning regimen where 1 Gy total body irradiation replaced the short course of rapamycin (Pilat et al., 2011 ). These protocols represent a major step forward to the clinic. However, they still rely on anti-CD154 treatment and this antibody is presently not usable in patients (see above). Different non-mutually exclusive strategies can be envisaged to avoid co-stimulatory-blockade. The use of hematopoietic or mesenchymal stem cells instead of bone-marrow cells could be an option, as this will significantly reduce the immunogenicity of the graft. Another strategy would be to improve the efficiency of the immunosuppression by injecting donor-specific Treg. Alloantigen-specific T cells survived longer and in several transplantation models gave substantially better results than polyclonal Tregs with irrelevant specificity (Joffre et al., 2004 , 2008 ; Nishimura et al., 2004 ; Golshayan et al., 2007 ).
Another aspect that still needs to be tested before translating Treg-based strategies into the clinic is represented by the antigen-specificity of the treatments. Indeed, if Treg activation is antigen specific, these cells exert their suppressor effector function in a non-antigen-specific-manner in vitro (Thornton and Shevach, 2000 ). If true in vivo , infused Treg may therefore inhibit protective immunity. However, it has been shown that hematopoietic chimerism/Treg-based therapy against allograft rejection is (at least) donor specific. A related issue is that tolerance to donor-antigen may be broken by (e.g., viral) infection (Welsh et al., 2000 ; Williams et al., 2001 ; Forman et al., 2002 ). It therefore also needs to be verified to what extent Treg-based therapies are resistant to infection. Experimental work will need to be performed to clarify these important issues.
Finally, infused Treg do not necessarily survive indefinitely and tolerance may therefore wane away with time. In other transplantation models, however, it was shown that a tolerant T cell population can render naïve T cells tolerant and even tolerogenic (Waldmann, 2010 ). Very recently it was shown that this so-called “infectious tolerance” depends on Treg that induce novel Treg required for persistence of tolerance to allografts (Kendal et al., 2011 ). Even if it remains to be shown that also infused Treg can cause infectious tolerance, it appears therefore that Treg can induce life-long tolerance to allografts.
Conclusion
The data discussed here indicate that induction of persistent hematopoietic chimerism combined with infusion of Treg with appropriate specificity efficiently leads to life-long tolerance to allografts in experimental animal models (Figure 1 ). Thus, and not very surprisingly so, the mechanisms involved in the maintenance of tolerance to self antigens also appear required for tolerance to donor antigens (Figure 2 ). More work will need to be performed to establish conditioning regimens compatible with clinical constraints and to assess immunocompetence of grafted animals. The validity of these conclusions for non-human primates and humans remains to be studied. Very substantial progress has been made in recent years in the induction of authentic immunological tolerance to allogeneic organ grafts, and transplant recipients may soon be able to live a life free of the fear of losing the graft and of the severe side effects of immunosuppressive drugs.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Adams A. B. Durham M. M. Kean L. Shirasugi N. Ha J. Williams M. A. Rees P. A. Cheung M. C. Mittelstaedt S. Bingaman A. W. Archer D. R. Pearson T. C. Waller E. K. Larsen C. P. ( 2001 ). Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression . J. Immunol. 167 , 1103 – 1111 11441122 10.4049/jimmunol.167.2.1103
Alard P. Matriano J. A. Socarras S. Ortega M.-A. Streilein J. W. ( 1995 ). Detection of donor-derived cells by polymerase chain reaction in neonatally tolerant mice . Transplantation 60 , 1125 – 1130 10.1097/00007890-199511270-00012 7482720
Anderson G. Partington K. M. Jenkinson E. J. ( 1998 ). Differential effects of peptide diversity and stromal cell type in positive and negative selection in the thymus . J. Immunol. 161 , 6599 – 6603 9862687
Aschenbrenner K. D’Cruz L. M. Vollmann E. H. Hinterberger M. Emmerich J. Swee L. K. Rolink A. Klein L. ( 2007 ). Selection of Foxp3(+) regulatory T cells specific for self antigen expressed and presented by Aire(+) medullary thymic epithelial cells . Nat. Immunol. 8 , 351 – 358 10.1038/ni1444 17322887
Baba T. Nakamoto Y. Mukaida N. ( 2009 ). Crucial contribution of thymic Sirp alpha+ conventional dendritic cells to central tolerance against blood-borne antigens in a CCR2-dependent manner . J. Immunol. 183 , 3053 – 3063 10.4049/jimmunol.0900438 19675159
Barber W. H. Mankin J. A. Laskow D. A. Deierhoi M. H. Julian B. A. Curtis J. J. Diethelm A. G. ( 1991 ). Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients . Transplantation 51 , 70 – 75 10.1097/00007890-199101000-00011 1987708
Bensinger S. J. Bandeira A. Jordan M. S. Caton A. J. Laufer T. M. ( 2001 ). Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+25+ immunoregulatory T cells . J. Exp. Med. 194 , 427 – 438 10.1084/jem.194.4.427 11514600 PMC2193499
Bigenzahn S. Blaha P. Koporc Z. Pree I. Selzer E. Bergmeister H. Wrba F. Heusser C. Wagner K. Muehlbacher F. Wekerle T. ( 2005 ). The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade . Am. J. Transplant. 5 , 1237 – 1247 10.1111/j.1600-6143.2005.00862.x 15888027
Billingham R. E. Brent L. Medawar P. B. ( 1953 ). Actively acquired tolerance of foreign cells . Nature 172 , 603 – 606 10.1038/172603a0 13099277
Billingham R. E. Lampkin G. H. Medawar P. B. Williams H. L. L. ( 1952 ). Tolerance to homografts, twin diagnosis, and the freemartin condition in cattle . Heredity 6 , 201 – 212 10.1038/hdy.1952.20
Blom D. Morrissey N. J. Mesonero C. Coppage M. Fisher T. Zuo X. J. Jordan S. C. Orloff M. S. ( 1996 ). Induction of specific tolerance through mixed hematopoietic chimerism prevents chronic renal allograft rejection in a rat model . Surgery 120 , 213 – 219 ; discussion 219–220. 10.1016/S0039-6060(96)80290-X 8751585
Boise L. H. Minn A. J. Noel P. J. June C. H. Accavitti M. A. Lindsten T. Thompson C. B. ( 1995 ). CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL . Immunity 3 , 87 – 98 10.1016/1074-7613(95)90161-2 7621080
Bonasio R. Scimone M. L. Schaerli P. Grabie N. Lichtman A. H. von Andrian U. H. ( 2006 ). Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus . Nat. Immunol. 7 , 1092 – 1100 10.1038/ni1106-1234b 16951687
Boyse E. A. Carswell E. A. Scheid M. P. Old L. J. ( 1973 ). Tolerance of Sk-incompatible skin grafts . Nature 244 , 441 – 442 10.1038/244441a0 4582498
Boyse E. A. Lance E. M. Carswell E. A. Cooper S. Old L. J. ( 1970 ). Rejection of skin allografts by radiation chimaeras: selective gene action in the specification of cell surface structure . Nature 227 , 901 – 903 10.1038/227901a0 4915405
Brocades Zaalberg A. Vos O. Bekkum Van D. W. ( 1957 ). Surviving rat skin grafts in mice . Nature 180 , 238 – 239 10.1038/180238a0 13451684
Brocker T. Riedinger M. Karjalainen K. ( 1997 ). Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo . J. Exp. Med. 185 , 541 – 550 10.1084/jem.185.3.541 9053454 PMC2196043
Buhler L. H. Spitzer T. R. Sykes M. Sachs D. H. Delmonico F. L. Tolkoff-Rubin N. Saidman S. L. Sackstein R. McAfee S. Dey B. Colby C. Cosimi A. B. ( 2002 ). Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease . Transplantation 74 , 1405 – 1409 10.1097/00007890-200211270-00011 12451240
Butcher J. A. Hariharan S. Adams M. B. Johnson C. P. Roza A. M. Cohen E. P. ( 1999 ). Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression . Clin. Transplant. 13 , 330 – 335 10.1034/j.1399-0012.1999.130409.x 10485375
Caridis D. T. Liegeois A. Barrett I. Monaco A. P. ( 1973 ). Enhanced survival of canine renal allografts of ALS- treated dogs given bone marrow . Transplant. Proc. 5 , 671 – 674 4572126
Chai J. G. Xue S. A. Coe D. Addey C. Bartok I. Scott D. Simpson E. Stauss H. J. Hori S. Sakaguchi S. Dyson J. ( 2005 ). Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance . Transplantation 79 , 1310 – 1316 10.1097/01.TP.0000159147.56408.9C 15912097
Colson Y. L. Wren S. M. Schuchert M. J. Patrene K. D. Johnson P. C. Boggs S. S. Ildstad S. T. ( 1995a ). A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers . J. Immunol. 155 , 4179 – 4188 7594573
Colson Y. L. Zadach K. Nalesnik M. Ildstad S. T. ( 1995b ). Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts . Transplantation 60 , 971 – 980 10.1097/00007890-199511000-00016 7491703
Cosimi A. B. Sachs D. H. ( 2004 ). Mixed chimerism and transplantation tolerance . Transplantation 77 , 943 – 946 10.1097/01.TP.0000117779.23431.3F 15077044
Crowe J. E. Jr. Sannella E. C. Pfeiffer S. Zorn G. L. Azimzadeh A. Newman R. Miller G. G. Pierson R. N. ( 2003 ). CD154 regulates primate humoral immunity to influenza . Am. J. Transplant. 3 , 680 – 688 10.1034/j.1600-6143.2003.00106.x 12780559
Domenig C. Sanchez-Fueyo A. Kurtz J. Alexopoulos S. P. Mariat C. Sykes M. Strom T. B. Zheng X. X. ( 2005 ). Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol . J. Immunol. 175 , 51 – 60 15972631 10.4049/jimmunol.175.1.51
Donckier V. Troisi R. Toungouz M. Colle I. Van Vlierberghe H. Jacquy C. Martiat P. Stordeur P. Zhou L. Boon N. Lambermont M. Schandene L. Van Laethem J. L. Noens L. Gelin M. de Hemptinne B. Goldman M. ( 2004 ). Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft . Transpl. Immunol. 13 , 139 – 146 10.1016/j.trim.2004.05.004 15380544
Donckier V. Wissing M. Bruyns C. Abramowicz D. Lybin M. Vanderhaeghen M. L. Goldman M. ( 1995 ). Critical role of interleukin 4 in the induction of neonatal transplantation tolerance . Transplantation 59 , 1571 – 1576 10.1097/00007890-199506000-00012 7778172
Emery D. McCullagh P. ( 1980 ). Immunological reactivity between chimeric cattle twins. I. Homograft reaction . Transplantation 29 , 4 – 9 10.1097/00007890-198001000-00003 6989041
Eto M. Mayumi H. Tomita Y. Yoshikai Y. Nomoto K. ( 1990 ). Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens . J. Exp. Med. 171 , 97 – 113 10.1084/jem.171.1.97 2136907 PMC2187648
Fehr T. Haspot F. Mollov J. Chittenden M. Hogan T. Sykes M. ( 2008a ). Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II . J. Immunol. 181 , 165 – 173 18566381 10.4049/jimmunol.181.1.165 PMC2734139
Fehr T. Wang S. Haspot F. Kurtz J. Blaha P. Hogan T. Chittenden M. Wekerle T. Sykes M. ( 2008b ). Rapid deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells . J. Immunol. 181 , 4371 – 4380 18768896 10.4049/jimmunol.181.6.4371 PMC2628539
Fontenot J. D. Rudensky A. Y. ( 2005 ). A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 . Nat. Immunol. 6 , 331 – 337 10.1038/ni1179 15785758
Forman D. Welsh R. M. Markees T. G. Woda B. A. Mordes J. P. Rossini A. A. Greiner D. L. ( 2002 ). Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms . J. Immunol. 168 , 6047 – 6056 12055213 10.4049/jimmunol.168.12.6047
Fuchimoto Y. Huang C. A. Yamada K. Gleit Z. L. Kitamura H. Griesemer A. Scheier-Dolberg R. Melendy E. White-Scharf M. E. Sachs D. H. ( 2001 ). Induction of kidney allograft tolerance through mixed chimerism in miniature swine . Transplant. Proc. 33 , 77 10.1016/S0041-1345(00)01934-5 11266710
Fuchimoto Y. Huang C. A. Yamada K. Shimizu A. Kitamura H. Colvin R. B. Ferrara V. Murphy M. C. Sykes M. White-Scharf M. Neville D. M. Jr. Sachs D. H. ( 2000 ). Mixed chimerism and tolerance without whole body irradiation in a large animal model . J. Clin. Invest. 105 , 1779 – 1789 10.1172/JCI8721 10862793 PMC378506
Fudaba Y. Spitzer T. R. Shaffer J. Kawai T. Fehr T. Delmonico F. Preffer F. Tolkoff-Rubin N. Dey B. R. Saidman S. L. Kraus A. Bonnefoix T. McAfee S. Power K. Kattleman K. Colvin R. B. Sachs D. H. Cosimi A. B. Sykes M. ( 2006 ). Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses . Am. J. Transplant. 6 , 2121 – 2133 10.1111/j.1600-6143.2006.01434.x 16796719
Fujisaki J. Wu J. Carlson A. L. Silberstein L. Putheti P. Larocca R. Gao W. Saito T. I. Lo Celso C. Tsuyuzaki H. Sato T. Cote D. Sykes M. Strom T. B. Scadden D. T. Lin C. P. ( 2011 ). In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche . Nature 474 , 216 – 219 10.1038/nature10160 21654805 PMC3725645
Golshayan D. Jiang S. Tsang J. Garin M. I. Mottet C. Lechler R. I. ( 2007 ). In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance . Blood 109 , 827 – 835 10.1182/blood-2006-05-025460 17003369
Guo Z. Wang J. Dong Y. Adams A. B. Shirasugi N. Kim O. Hart J. Newton-West M. Pearson T. C. Larsen C. P. Newell K. A. ( 2003 ). Long-term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion . Am. J. Transplant. 3 , 1091 – 1098 10.1034/j.1600-6143.2003.00127.x 12919088
Guzzetta P. C. Sundt T. M. Suzuki T. Mixon A. Rosengard B. R. Sachs D. H. ( 1991 ). Induction of kidney transplantation tolerance across major histocompatibility complex barriers by bone marrow transplantation in miniature swine . Transplantation 51 , 862 – 866 10.1097/00007890-199104000-00024 2014544
Hanash A. M. Levy R. B. ( 2005 ). Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation . Blood 105 , 1828 – 1836 10.1182/blood-2004-08-3213 15494429
Hartner W. C. De Fazio S. R. Maki T. Markees T. G. Monaco A. P. Gozzo J. J. ( 1986 ). Prolongation of renal allograft survival in antilymphocyte-serum-treated dogs by postoperative injection of density-gradient-fractionated donor bone marrow . Transplantation 42 , 593 – 597 10.1097/00007890-198612000-00004 2947358
Hawiger D. Inaba K. Dorsett Y. Guo M. Mahnke K. Rivera M. Ravetch J. V. Steinman R. M. Nussenzweig M. C. ( 2001 ). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo . J. Exp. Med. 194 , 769 – 779 10.1084/jem.194.6.769 11560993 PMC2195961
Henn V. Slupsky J. R. Grafe M. Anagnostopoulos I. Forster R. Muller-Berghaus G. Kroczek R. A. ( 1998 ). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells . Nature 391 , 591 – 594 10.1038/35393 9468137
Hogquist K. A. Baldwin T. A. Jameson S. C. ( 2005 ). Central tolerance: learning self-control in the thymus . Nat. Rev. Immunol. 5 , 772 – 782 10.1038/nri1707 16200080
Horner B. M. Cina R. A. Wikiel K. J. Lima B. Ghazi A. Lo D. P. Yamada K. Sachs D. H. Huang C. A. ( 2006 ). Predictors of organ allograft tolerance following hematopoietic cell transplantation . Am. J. Transplant. 6 , 2894 – 2902 10.1111/j.1600-6143.2006.01563.x 17294522
Hsieh C. S. Liang Y. Tyznik A. J. Self S. G. Liggitt D. Rudensky A. Y. ( 2004 ). Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors . Immunity 21 , 267 – 277 10.1016/j.immuni.2004.07.009 15308106
Huang C. A. Fuchimoto Y. Scheier-Dolberg R. Murphy M. C. Neville D. M. Jr. Sachs D. H. ( 2000 ). Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model . J. Clin. Invest. 105 , 173 – 181 10.1172/JCI7913 10642595 PMC377429
Hudrisier D. Feau S. Bonnet V. Romagnoli P. van Meerwijk J. P. M. ( 2003 ). In vivo unresponsiveness of T lymphocyte induced by thymic medullary epithelium requires antigen presentation by radioresistant cells . Immunology 108 , 24 – 31 10.1046/j.1365-2567.2003.01546.x 12519299 PMC1782865
Ildstad S. T. Sachs D. H. ( 1984 ). Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts . Nature 307 , 168 – 170 10.1038/307168a0 6361574
Issa F. Wood K. J. ( 2010 ). CD4+ regulatory T cells in solid organ transplantation . Curr. Opin. Organ. Transplant . 10.1097/MOT.0b013e32834017ae 20881492 PMC3198838
Iwai T. Tomita Y. Okano S. Shimizu I. Yasunami Y. Kajiwara T. Yoshikai Y. Taniguchi M. Nomoto K. Yasui H. ( 2006 ). Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance . J. Immunol. 177 , 8400 – 8409 17142737 10.4049/jimmunol.177.12.8400
Jenkinson E. J. Anderson G. Owen J. J. ( 1992 ). Studies on T cell maturation on defined thymic stromal cell populations in vitro . J. Exp. Med. 176 , 845 – 853 10.1084/jem.176.3.845 1512547 PMC2119352
Joffre O. Gorsse N. Romagnoli P. Hudrisier D. van Meerwijk J. P. M. ( 2004 ). Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes . Blood 103 , 4216 – 4221 10.1182/blood-2004-01-0005 14976053 PMC2516529
Joffre O. Santolaria T. Calise D. Al Saati T. Hudrisier D. Romagnoli P. van Meerwijk J. P. M. ( 2008 ). Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes . Nat. Med. 14 , 88 – 92 10.1038/nm1688 18066074 PMC2443705
Joffre O. van Meerwijk J. P. M. ( 2006 ). CD4+CD25+ regulatory T lymphocytes in bone marrow transplantation . Semin. Immunol. 18 , 128 – 135 10.1016/j.smim.2006.01.005 16458534 PMC1950263
Ju S. T. Panka D. J. Cui H. Ettinger R. el-Khatib M. Sherr D. H. Stanger B. Z. Marshak-Rothstein A. ( 1995 ). Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation . Nature 373 , 444 – 448 10.1038/373444a0 7530337
Kahan B. D. ( 2003 ). Individuality: the barrier to optimal immunosuppression . Nat. Rev. Immunol. 3 , 831 – 838 10.1038/nri1204 14523389
Kappler J. W. Roehm N. Marrack P. ( 1987a ). T cell tolerance by clonal elimination in the thymus . Cell 49 , 273 – 280 10.1016/0092-8674(87)90567-8 3494522
Kappler J. W. Wade T. White J. Kushnir E. Blackman M. Bill J. Roehm N. Marrack P. ( 1987b ). A T cell receptor V beta segment that imparts reactivity to a class II major histocompatibility complex product . Cell 49 , 263 – 271 10.1016/0092-8674(87)90567-8 3471350
Kappler J. W. Staerz U. White J. Marrack P. C. ( 1988 ). Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex . Nature 332 , 35 – 40 10.1038/332035a0 3126396
Karim M. Feng G. Wood K. J. Bushell A. R. ( 2005 ). CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation . Blood 105 , 4871 – 4877 10.1182/blood-2004-10-3888 15713793
Kawai T. Andrews D. Colvin R. B. Sachs D. H. Cosimi A. B. ( 2000 ). Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand . Nat. Med. 6 , 114 10.1038/72162 10655073
Kawai T. Cosimi A. B. Colvin R. B. Powelson J. Eason J. Kozlowski T. Sykes M. Monroy R. Tanaka M. Sachs D. H. ( 1995 ). Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys . Transplantation 59 , 256 – 262 10.1097/00007890-199501000-00018 7839449
Kawai T. Cosimi A. B. Spitzer T. R. Tolkoff-Rubin N. Suthanthiran M. Saidman S. L. Shaffer J. Preffer F. I. Ding R. Sharma V. Fishman J. A. Dey B. Ko D. S. Hertl M. Goes N. B. Wong W. Williams W. W. Jr. Colvin R. B. Sykes M. Sachs D. H. ( 2008 ). HLA-mismatched renal transplantation without maintenance immunosuppression . N. Engl. J. Med. 358 , 353 – 361 10.1056/NEJMoa071074 18216355 PMC2819046
Kawai T. Cosimi A. B. Wee S. L. Houser S. Andrews D. Sogawa H. Phelan J. Boskovic S. Nadazdin O. Abrahamian G. Colvin R. B. Sachs D. H. Madsen J. C. ( 2002 ). Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys . Transplantation 73 , 1757 – 1764 10.1097/00007890-200206150-00011 12084998
Kawai T. Poncelet A. Sachs D. H. Mauiyyedi S. Boskovic S. Wee S. L. Ko D. S. Bartholomew A. Kimikawa M. Hong H. Z. Abrahamian G. Colvin R. B. Cosimi A. B. ( 1999 ). Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance . Transplantation 68 , 1767 – 1775 10.1097/00007890-199912150-00022 10609955
Kawai T. Sogawa H. Boskovic S. Abrahamian G. Smith R. N. Wee S. L. Andrews D. Nadazdin O. Koyama I. Sykes M. Winn H. J. Colvin R. B. Sachs D. H. Cosimi A. B. ( 2004 ). CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates . Am. J. Transplant. 4 , 1391 – 1398 10.1111/j.1600-6143.2004.00523.x 15307826
Kendal A. R. Chen Y. Regateiro F. S. Ma J. Adams E. Cobbold S. P. Hori S. Waldmann H. ( 2011 ). Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance . J. Exp. Med. 208 , 2043 – 2053 10.1084/jem.20110767 21875958 PMC3182049
Khan A. Tomita Y. Sykes M. ( 1996 ). Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance . Transplantation 62 , 380 – 387 10.1097/00007890-199608150-00014 8779687
Kimikawa M. Kawai T. Sachs D. H. Colvin R. B. Bartholomew A. Cosimi A. B. ( 1997a ). Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys . Transplant. Proc. 29 , 1218 10.1016/S0041-1345(96)00642-2 9123281
Kimikawa M. Sachs D. H. Colvin R. B. Bartholomew A. Kawai T. Cosimi A. B. ( 1997b ). Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys . Transplantation 64 , 709 – 716 10.1097/00007890-199709150-00008 9311707
Kleindienst P. Chretien I. Winkler T. Brocker T. ( 2000 ). Functional comparison of thymic B cells and dendritic cells in vivo . Blood 95 , 2610 – 2616 10753841
Koyama I. Kawai T. Andrews D. Boskovic S. Nadazdin O. Wee S. L. Sogawa H. Wu D. L. Smith R. N. Colvin R. B. Sachs D. H. Cosimi A. B. ( 2004 ). Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates . Transplantation 77 , 460 – 462 10.1097/01.TP.0000110291.29370.C0 14966427
Kurtz J. Shaffer J. Lie A. Anosova N. Benichou G. Sykes M. ( 2004 ). Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells . Blood 103 , 4336 – 4343 10.1182/blood-2003-08-2642 14962909
Larsen C. P. Elwood E. T. Alexander D. Z. Ritchie S. C. Hendrix R. Tucker-Burden C. Cho H. R. Aruffo A. Hollenbaugh D. Linsley P. S. Winn K. J. Pearson T. C. ( 1996 ). Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways . Nature 381 , 434 – 438 10.1038/381434a0 8632801
Le Douarin N. Corbel C. Bandeira A. Thomas-Vaslin V. Modigliani Y. Coutinho A. Salaun J. ( 1996 ). Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells . Immunol. Rev. 149 , 35 – 53 10.1111/j.1600-065X.1996.tb00898.x 9005218
Lenardo M. J. ( 1991 ). Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis . Nature 353 , 858 – 861 10.1038/353858a0 1944559
Li X. C. Turka L. A. ( 2010 ). An update on regulatory T cells in transplant tolerance and rejection . Nat. Rev. Nephrol. 6 , 577 – 583 10.1038/nrneph.2010.101 20683480
Lubaroff D. M. Silvers W. K. ( 1973 ). The importance of chimerism in maintaining tolerance of skin allografts in mice . J. Immunol. 111 , 65 – 71 4576586
Luo B. Chan W. F. Shapiro A. M. Anderson C. C. ( 2007 ). Non-myeloablative mixed chimerism approaches and tolerance, a split decision . Eur. J. Immunol. 37 , 1233 – 1242 10.1002/eji.200636938 17390394
Luo B. Nanji S. A. Schur C. D. Pawlick R. L. Anderson C. C. Shapiro A. M. ( 2005 ). Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning . Transplantation 80 , 370 – 377 10.1097/01.tp.0000167724.38038.ae 16082333
Luther S. A. Acha-Orbea H. ( 1997 ). Mouse mammary tumor virus: immunological interplays between virus and host . Adv. Immunol. 65 , 139 – 243 10.1016/S0065-2776(08)60743-9 9238510
MacDonald H. R. Pedrazzini T. Schneider R. Louis J. A. Zinkernagel R. M. Hengartner H. ( 1988a ). Intrathymic elimination of Mlsa-reactive (V beta 6+) cells during neonatal tolerance induction to Mlsa-encoded antigens . J. Exp. Med. 167 , 2005 – 2010 10.1084/jem.167.4.1341 2968436 PMC2189684
MacDonald H. R. Schneider R. Lees R. K. Howe R. C. Acha-Orbea H. Festenstein H. Zinkernagel R. M. Hengartner H. ( 1988b ). T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens . Nature 332 , 40 – 45 10.1038/332040a0 3126397
Madsen J. C. Yamada K. Allan J. S. Choo J. K. Erhorn A. E. Pins M. R. Vesga L. Slisz J. K. Sachs D. H. ( 1998 ). Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine . Transplantation 65 , 304 – 313 10.1097/00007890-199802150-00002 9484744
Main J. M. Prehn R. T. ( 1955 ). Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow . J. Natl. Cancer Inst. 15 , 1023 – 1029 13233946
Manilay J. O. Pearson D. A. Sergio J. J. Swenson K. G. Sykes M. ( 1998 ). Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen . Transplantation 66 , 96 – 102 10.1097/00007890-199807150-00015 9679828
Mapara M. Y. Pelot M. Zhao G. Swenson K. Pearson D. Sykes M. ( 2001 ). Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance . Biol. Blood Marrow Transplant. 7 , 646 – 655 10.1053/bbmt.2001.v7.pm11787527 11787527
Matzinger P. Guerder S. ( 1989 ). Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 338 , 74 – 76 10.1038/338074a0 2783992
Mayumi H. Good R. A. ( 1989 ). Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide . J. Exp. Med. 169 , 213 – 238 10.1084/jem.169.1.213 2642528 PMC2189174
McDaniel D. O. Naftilan J. Hulvey K. Shaneyfelt S. Lemons J. A. Lagoo-Deenadayalan S. Hudson S. Diethelm A. G. Barber W. H. ( 1994 ). Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow . Transplantation 57 , 852 – 856 10.1097/00007890-199403270-00014 8154031
Meier-Kriesche H. U. Kaplan B. ( 2011 ). The search for CNI-free immunosuppression: no free lunch . Am. J. Transplant. 11 , 1355 – 1356 10.1111/j.1600-6143.2011.03541.x 21564526
Metzler B. Gfeller P. Bigaud M. Li J. Wieczorek G. Heusser C. Lake P. Katopodis A. ( 2004 ). Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection . J. Immunol. 173 , 7025 – 7036 15557200 10.4049/jimmunol.173.11.7025
Mezrich J. D. Kesselheim J. A. Johnston D. R. Yamada K. Sachs D. H. Madsen J. C. ( 2003a ). The role of regulatory cells in miniature swine rendered tolerant to cardiac allografts by donor kidney cotransplantation . Am. J. Transplant. 3 , 1107 – 1115 10.1046/j.1600-6143.2003.00202.x 12919090
Mezrich J. D. Yamada K. Lee R. S. Mawulawde K. Benjamin L. C. Schwarze M. L. Maloney M. E. Amoah H. C. Houser S. L. Sachs D. H. Madsen J. C. ( 2003b ). Induction of tolerance to heart transplants by simultaneous cotransplantation of donor kidneys may depend on a radiation-sensitive renal-cell population . Transplantation 76 , 625 – 631 10.1097/01.TP.0000079926.80833.42 12973099
Mineo D. Ricordi C. Xu X. Pileggi A. Garcia-Morales R. Khan A. Baidal D. A. Han D. Monroy K. Miller J. Pugliese A. Froud T. Inverardi L. Kenyon N. S. Alejandro R. ( 2008 ). Combined islet and hematopoietic stem cell allotransplantation: a clinical pilot trial to induce chimerism and graft tolerance . Am. J. Transplant. 8 , 1262 – 1274 10.1111/j.1600-6143.2008.02230.x 18444924
Monaco A. P. ( 2003 ). Chimerism in organ transplantation: conflicting experiments and clinical observations . Transplantation 75 , 13S – 16S 10.1097/00007890-200305271-00002 12819484
Nadig S. N. Wieckiewicz J. Wu D. C. Warnecke G. Zhang W. Luo S. Schiopu A. Taggart D. P. Wood K. J. ( 2010 ). In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells . Nat. Med. 16 , 809 – 813 10.1038/nm.2154 20473306 PMC2929438
Nishimura E. Sakihama T. Setoguchi R. Tanaka K. Sakaguchi S. ( 2004 ). Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells . Int. Immunol. 16 , 1189 – 1201 10.1093/intimm/dxh122 15237110
Orloff M. S. DeMara E. M. Coppage M. L. Leong N. Fallon M. A. Sickel J. Zuo X. J. Prehn J. Jordan S. C. ( 1995 ). Prevention of chronic rejection and graft arteriosclerosis by tolerance induction . Transplantation 59 , 282 – 288 10.1097/00007890-199501000-00022 7839452
Owen R. D. ( 1945 ). Immunogenic consequences of vascular anastomoses between bovine twins . Science 102 , 400 – 401 10.1126/science.102.2651.400 17755278
Pearson T. C. Madsen J. C. Larsen C. P. Morris P. J. Wood K. J. ( 1992 ). Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody . Transplantation 54 , 475 – 483 10.1097/00007890-199209000-00018 1384183
Pilat N. Baranyi U. Klaus C. Jaeckel E. Mpofu N. Wrba F. Golshayan D. Muehlbacher F. Wekerle T. ( 2010 ). Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning . Am. J. Transplant. 10 , 751 – 762 10.1111/j.1600-6143.2010.03018.x 20148810 PMC2856406
Pilat N. Klaus C. Gattringer M. Jaeckel E. Wrba F. Golshayan D. Baranyi U. Wekerle T. ( 2011 ). Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model . Transplantation 92 , 280 – 288 10.1097/TP.0b013e3182241133 21697774
Pircher H. Brduscha K. Steinhoff U. Kasai M. Mizuochi T. Zinkernagel R. M. Hengartner H. Kyewski B. Muller K. P. ( 1993 ). Tolerance induction by clonal deletion of CD4 + 8 + thymocytes in vitro does not require dedicated antigen-presenting cells . Eur. J. Immunol. 23 , 669 – 674 10.1002/eji.1830230315 8095457
Pircher H. Muller K. P. Kyewski B. A. Hengartner H. ( 1992 ). Thymocytes can tolerize thymocytes by clonal deletion in vitro . Int. Immunol. 4 , 1065 – 1069 10.1093/intimm/4.9.1065 1390437
Porcheray F. Wong W. Saidman S. L. De Vito J. Girouard T. C. Chittenden M. Shaffer J. Tolkoff-Rubin N. Dey B. R. Spitzer T. R. Colvin R. B. Cosimi A. B. Kawai T. Sachs D. H. Sykes M. Zorn E. ( 2009 ). B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans . Am. J. Transplant. 9 , 2126 – 2135 10.1111/j.1600-6143.2009.02738.x 19624570 PMC2837587
Proietto A. I. van Dommelen S. Zhou P. Rizzitelli A. D’Amico A. Steptoe R. J. Naik S. H. Lahoud M. H. Liu Y. Zheng P. Shortman K. Wu L. ( 2008 ). Dendritic cells in the thymus contribute to T-regulatory cell induction . Proc. Natl. Acad. Sci. U.S.A. 105 , 19869 – 19874 10.1073/pnas.0810268105 19073916 PMC2604962
Qin S. X. Wise M. Cobbold S. P. Leong L. Kong Y. C. Parnes J. R. Waldmann H. ( 1990 ). Induction of tolerance in peripheral T cells with monoclonal antibodies . Eur. J. Immunol. 20 , 2737 – 2745 10.1002/eji.1830201231 1702726
Rammensee H. G. Kroschewski R. Frangoulis B. ( 1989 ). Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells . Nature 339 , 541 – 544 10.1038/339541a0 2525232
Ribot J. Enault G. Pilipenko S. Huchenq A. Calise M. Hudrisier D. Romagnoli P. van Meerwijk J. P. M. ( 2007 ). Shaping of the autoreactive regulatory T cell repertoire by thymic cortical positive selection . J. Immunol. 179 , 6741 – 6748 17982064 10.4049/jimmunol.179.10.6741 PMC2577800
Ribot J. Romagnoli P. van Meerwijk J. P. M. ( 2006 ). Agonist ligands expressed by thymic epithelium enhance positive selection of regulatory T lymphocytes from precursors with a normally diverse TCR repertoire . J. Immunol. 177 , 1101 – 1107 16818767 10.4049/jimmunol.177.2.1101 PMC2346540
Rocken M. ( 1996 ). Immune deviation–the third dimension of nondeletional T cell tolerance . Immunol. Rev. 149 , 175 – 194 10.1111/j.1600-065X.1996.tb00904.x 9005214
Romagnoli P. Hudrisier D. van Meerwijk J. P. M. ( 2002 ). Preferential recognition of self-antigens despite normal thymic deletion of CD4+CD25+ regulatory T cells . J. Immunol. 168 , 1644 – 1648 11823492 10.4049/jimmunol.168.4.1644
Romagnoli P. Hudrisier D. van Meerwijk J. P. M. ( 2005 ). Molecular signature of recent thymic selection events on effector and regulatory CD4+ T lymphocytes . J. Immunol. 175 , 5751 – 5758 16237066 10.4049/jimmunol.175.9.5751 PMC2346488
Romagnoli P. Ribot J. Tellier J. van Meerwijk J. P. M. ( 2008 ). “Thymic and peripheral generation of CD4+Foxp3+ regulatory T cells,” in Regulatory T cells and Clinical Application , ed. Jiang S. ( Springer Science+Business Media ), 29 – 55
Russell J. H. ( 1995 ). Activation-induced death of mature T cells in the regulation of immune responses . Curr. Opin. Immunol. 7 , 382 – 388 10.1016/0952-7915(95)80092-1 7546404
Russell P. S. Chase C. M. Sykes M. Ito H. Shaffer J. Colvin R. B. ( 2001 ). Tolerance, mixed chimerism, and chronic transplant arteriopathy . J. Immunol. 167 , 5731 – 5740 11698446 10.4049/jimmunol.167.10.5731
Sakaguchi S. Ono M. Setoguchi R. Yagi H. Hori S. Fehervari Z. Shimizu J. Takahashi T. Nomura T. ( 2006 ). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease . Immunol. Rev. 212 , 8 – 27 10.1111/j.0105-2896.2006.00425.x 16903903
Sakaguchi S. Sakaguchi N. Asano M. Itoh M. Toda M. ( 1995 ). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases . J. Immunol. 155 , 1151 – 1164 7636184
Scandling J. D. Busque S. Dejbakhsh-Jones S. Benike C. Millan M. T. Shizuru J. A. Hoppe R. T. Lowsky R. Engleman E. G. Strober S. ( 2008 ). Tolerance and chimerism after renal and hematopoietic-cell transplantation . N. Engl. J. Med. 358 , 362 – 368 10.1056/NEJMoa074191 18216356
Scheid M. Boyse E. A. Carswell E. A. Old L. J. ( 1972 ). Serologically demonstrable alloantigens of mouse epidermal cells . J. Exp. Med. 135 , 938 – 955 10.1084/jem.135.4.938 4553016 PMC2139153
Shevach E. M. DiPaolo R. A. Andersson J. Zhao D. M. Stephens G. L. Thornton A. M. ( 2006 ). The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells . Immunol. Rev. 212 , 60 – 73 10.1111/j.0105-2896.2006.00415.x 16903906
Shirasugi N. Adams A. B. Durham M. M. Lukacher A. E. Xu H. Rees P. Cowan S. R. Williams M. A. Pearson T. C. Larsen C. P. ( 2002 ). Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens . J. Immunol. 169 , 2677 – 2684 12193741 10.4049/jimmunol.169.5.2677
Slavin S. Reitz B. Bieber C. P. Kaplan H. S. Strober S. ( 1978 ). Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts . J. Exp. Med. 147 , 700 – 707 10.1084/jem.147.4.963 147301 PMC2184184
Slupsky J. R. Kalbas M. Willuweit A. Henn V. Kroczek R. A. Muller-Berghaus G. ( 1998 ). Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 . Thromb. Haemost. 80 , 1008 – 1014 9869175
Sorof J. M. Koerper M. A. Portale A. A. Potter D. DeSantes K. Cowan M. ( 1995 ). Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation . Transplantation 59 , 1633 – 1635 7778182
Spitzer T. R. Delmonico F. Tolkoff-Rubin N. McAfee S. Sackstein R. Saidman S. Colby C. Sykes M. Sachs D. H. Cosimi A. B. ( 1999 ). Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism . Transplantation 68 , 480 – 484 10.1097/00007890-199908270-00006 10480403
Steinmuller D. Lofgreen J. S. ( 1974 ). Differential survival of skin and heart allografts in radiation chimaeras provides further evidence for Sk histocompatibility antigen . Nature 248 , 796 – 797 10.1038/248796a0 4599086
Stone W. H. Cragle R. G. Johnson D. F. Bacon J. A. Bendel S. Korda N. ( 1971 ). Long-term observations of skin grafts between chimeric cattle twins . Transplantation 12 , 421 – 428 10.1097/00007890-197112000-00002 4941046
Stone W. H. Cragle R. G. Swanson E. W. Brown D. G. ( 1965 ). Skin grafts: delayed rejection between pairs of cattle twins showing erythrocyte chimerism . Science 148 , 1335 – 1336 10.1126/science.148.3675.1335 14281713
Streilein J. W. ( 1991 ). Neonatal tolerance of H-2 alloantigens. Procuring graft acceptance the “old-fashioned” way . Transplantation 52 , 1 – 10 10.1097/00007890-199107000-00001 1858135
Streilein J. W. Klein J. ( 1977 ). Neonatal tolerance induction across regions of H-2 complex . J. Immunol. 119 , 2147 – 2150 334985
Strober S. Modry D. L. Hoppe R. T. Pennock J. L. Bieber C. P. Holm B. I. Jamieson S. W. Stinson E. B. Schroder J. Suomalainen H. ( 1984 ). Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin . J. Immunol. 132 , 1013 – 1018 6361129
Thomas J. Carver M. Cunningham P. Park K. Gonder J. Thomas F. ( 1987 ). Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism . Transplantation 43 , 332 – 338 10.1097/00007890-198703000-00002 3103273
Thomas J. M. Carver F. M. Foil M. B. Hall W. R. Adams C. Fahrenbruch G. B. Thomas F. T. ( 1983 ). Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys . Transplantation 36 , 104 – 106 10.1097/00007890-198307000-00021 6346606
Thornton A. M. Shevach E. M. ( 2000 ). Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific . J. Immunol. 164 , 183 – 190 10605010 10.4049/jimmunol.164.1.183
Tomita Y. Khan A. Sykes M. ( 1994 ). Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen . J. Immunol. 153 , 1087 – 1098 8027542
Tomita Y. Mayumi H. Eto M. Nomoto K. ( 1990a ). Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J. Immunol. 144 , 463 – 473 2136891
Tomita Y. Nishimura Y. Harada N. Eto M. Ayukawa K. Yoshikai Y. Nomoto K. ( 1990b ). Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion . J. Immunol. 145 , 4026 – 4036 2147933
Trentin J. J. ( 1956 ). Mortality and skin transplantability in x-irradiated mice receiving isologous, homologous or heterologous bone marrow . Proc. Soc. Exp. Biol. Med. 92 , 688 – 693 13370496 10.3181/00379727-92-22582
Tsang J. Y. Tanriver Y. Jiang S. Xue S. A. Ratnasothy K. Chen D. Stauss H. J. Bucy R. P. Lombardi G. Lechler R. ( 2008 ). Conferring indirect allospecificity on CD4CD25 Tregs by TCR gene transfer favors transplantation tolerance in mice . J. Clin. Invest. 118 , 3619 – 3628 10.1172/JCI33185 18846251 PMC2564608
van Meerwijk J. P. M. MacDonald H. R. ( 1999 ). In vivo T lymphocyte tolerance in the absence of thymic clonal deletion mediated by haematopoietic cells . Blood 93 , 3856 – 3862 10339493
Van Parijs L. Ibraghimov A. Abbas A. K. ( 1996 ). The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance . Immunity 4 , 321 – 328 10.1016/S1074-7613(00)80440-9 8624822
Waldmann H. ( 2010 ). Tolerance: an overview and perspectives . Nat. Rev. Nephrol. 6 , 569 – 576 10.1038/nrneph.2010.108 20717099
Walker L. S. Abbas A. K. ( 2002 ). The enemy within: keeping self-reactive T cells at bay in the periphery . Nat. Rev. Immunol. 2 , 11 – 19 10.1038/nri701 11908514
Watanabe N. Wang Y. H. Lee H. K. Ito T. Wang Y. H. Cao W. Liu Y. J. ( 2005 ). Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus . Nature 436 , 1181 – 1185 10.1038/nature03886 16121185
Wekerle T. Kurtz J. Ito H. Ronquillo J. V. Dong V. Zhao G. Shaffer J. Sayegh M. H. Sykes M. ( 2000 ). Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment . Nat. Med. 6 , 464 – 469 10.1038/74731 10742157
Wekerle T. Kurtz J. Sayegh M. Ito H. Wells A. Bensinger S. Shaffer J. Turka L. Sykes M. ( 2001 ). Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death . J. Immunol. 166 , 2311 – 2316 11160287 10.4049/jimmunol.166.4.2311
Wekerle T. Sayegh M. H. Hill J. Zhao Y. Chandraker A. Swenson K. G. Zhao G. Sykes M. ( 1998 ). Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance . J. Exp. Med. 187 , 2037 – 2044 10.1084/jem.187.12.2037 9625763 PMC2212372
Wekerle T. Sykes M. ( 1999 ). Mixed chimerism as an approach for the induction of transplantation tolerance . Transplantation 68 , 459 – 467 10.1097/00007890-199908270-00001 10480398
Welsh R. M. Markees T. G. Woda B. A. Daniels K. A. Brehm M. A. Mordes J. P. Greiner D. L. Rossini A. A. ( 2000 ). Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody . J. Virol. 74 , 2210 – 2218 10.1128/JVI.74.5.2210-2218.2000 10666251 PMC111702
Williams M. A. Tan J. T. Adams A. B. Durham M. M. Shirasugi N. Whitmire J. K. Harrington L. E. Ahmed R. Pearson T. C. Larsen C. P. ( 2001 ). Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance . J. Immunol. 167 , 4987 – 4995 11673506 10.4049/jimmunol.167.9.4987
Wirnsberger G. Mair F. Klein L. ( 2009 ). Regulatory T cells differentiation of thymocytes does not require a dedicated antigen-presenting cell but is under T cell-intrinsic developmental control . Proc. Natl. Acad. Sci. U.S.A . 10.1073/pnas.0901877106 19515822 PMC2694684
Wood P. J. Streilein J. W. ( 1982 ). Ontogeny of acquired immunological tolerance to H-2 alloantigens . Eur. J. Immunol. 12 , 188 – 194 10.1002/eji.1830120304 6212255
Wren S. M. Hronakes M. L. Ildstad S. T. ( 1993 ). CD4+ T cells, but not CD8+ T cells, mediate the breaking of tolerance in mixed allogeneic chimeras (B10 + B10.BR–>B10) . Transplantation 55 , 1382 – 1389 10.1097/00007890-199306000-00033 8100092
Wu L. Shortman K. ( 2005 ). Heterogeneity of thymic dendritic cells . Semin. Immunol. 17 , 304 – 312 10.1016/j.smim.2005.05.001 15946853
Wu O. Levy A. R. Briggs A. Lewis G. Jardine A. ( 2009 ). Acute rejection and chronic nephropathy: a systematic review of the literature . Transplantation 87 , 1330 – 1339 10.1097/TP.0b013e3181a236e0 19424033
Yamada K. Choo J. K. Allan J. S. Erhorn A. E. Menard M. T. Mawulawde K. Slisz J. K. Aretz H. T. Shimizu A. Sachs D. H. Madsen J. C. ( 1999 ). The effect of thymectomy on tolerance induction and cardiac allograft vasculopathy in a miniature swine heart/kidney transplantation model . Transplantation 68 , 485 – 491 10.1097/00007890-199912150-00011 10480404